Literature DB >> 21175266

Hypoglycemia risk and glucose variability indices derived from routine self-monitoring of blood glucose are related to laboratory measures of insulin sensitivity and epinephrine counterregulation.

Achilleas N Pitsillides1, Stacey M Anderson, Boris Kovatchev.   

Abstract

BACKGROUND: the widely held assumptions that in type 1 diabetes glucose variability may correlate with insulin sensitivity and impaired epinephrine counterregulation have not been studied directly. Here we investigate possible relationships between outpatient measures of glucose variability and risk for hypoglycemia with physiological characteristics: insulin sensitivity and hypoglycemia counterregulation.
METHODS: thirty-four subjects with type 1 diabetes (14 women, 20 men; 37 ± 2.1 years old; glycosylated hemoglobin [HbA1c], 7.6  ±  0.21%) performed self-monitoring of blood glucose (SMBG) for a month, followed by an inpatient hyperinsulinemic euglycemic and hypoglycemic clamp. SMBG field data were used to calculate measures of glucose variability and risk of hypoglycemia, while the clamp procedure was used to evaluate insulin sensitivity and epinephrine response during induced hypoglycemia. Spearman partial correlations adjusted for age, duration of diabetes, body mass index, gender, and HbA1c were used to assess the relationship between the field indices of glucose variability and the physiological characteristics of diabetes.
RESULTS: two glucose variability measures correlated positively (P < 0.01) with insulin sensitivity: the Average Daily Risk Range (ADRR) (ρ = 0.5) and the Glycemic Lability Index (ρ = 0.48). The Low Blood Glucose Index, a measure of the risk for hypoglycemia, and the ADRR correlated negatively with maximum epinephrine response during hypoglycemia: ρ = -0.46, P < 0.01 and ρ = -0.4, P = 0.03, respectively.
CONCLUSIONS: higher insulin sensitivity and lower epinephrine response during hypoglycemia are related to increased glucose variability (as quantified by the ADRR), irrespective of HbA1c and other patient characteristics. Lower epinephrine relates to risk for hypoglycemia as well.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21175266      PMCID: PMC3025766          DOI: 10.1089/dia.2010.0103

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  28 in total

1.  Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose.

Authors:  B P Kovatchev; D J Cox; L S Farhy; M Straume; L Gonder-Frederick; W L Clarke
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index.

Authors:  A Caumo; R N Bergman; C Cobelli
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

3.  Mean amplitude of glycemic excursions, a measure of diabetic instability.

Authors:  F J Service; G D Molnar; J W Rosevear; E Ackerman; L C Gatewood; W F Taylor
Journal:  Diabetes       Date:  1970-09       Impact factor: 9.461

4.  Effects of recurrent hyperinsulinemia with and without hypoglycemia on counterregulation in diabetic rats.

Authors:  Karen Inouye; Kathy Shum; Owen Chan; Julian Mathoo; Stephen G Matthews; Mladen Vranic
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-06       Impact factor: 4.310

5.  Blunted Counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes: response to the Diabetes Research in Children Network (DirecNet) Study Group.

Authors:  Alex J Graveling; Roderick E Warren; Brian M Frier
Journal:  Diabetes Care       Date:  2010-05       Impact factor: 19.112

Review 6.  Blood glucose monitoring technology: translating data into practice.

Authors:  Irl B Hirsch
Journal:  Endocr Pract       Date:  2004 Jan-Feb       Impact factor: 3.443

7.  Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?

Authors:  J Bragd; U Adamson; L B Bäcklund; P E Lins; E Moberg; P Oskarsson
Journal:  Diabetes Metab       Date:  2008-09-27       Impact factor: 6.041

8.  Quantitative estimation of insulin sensitivity.

Authors:  R N Bergman; Y Z Ider; C R Bowden; C Cobelli
Journal:  Am J Physiol       Date:  1979-06

9.  Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data.

Authors:  Boris P Kovatchev; Daniel J Cox; Anand Kumar; Linda Gonder-Frederick; William L Clarke
Journal:  Diabetes Technol Ther       Date:  2003       Impact factor: 6.118

10.  Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation.

Authors:  Edmond A Ryan; Tami Shandro; Kristy Green; Breay W Paty; Peter A Senior; David Bigam; A M James Shapiro; Marie-Christine Vantyghem
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

View more
  8 in total

1.  Are Risk Indices Derived From CGM Interchangeable With SMBG-Based Indices?

Authors:  Chiara Fabris; Stephen D Patek; Marc D Breton
Journal:  J Diabetes Sci Technol       Date:  2015-08-14

Review 2.  Average daily risk range as a measure for clinical research and routine care.

Authors:  Susana R Patton; Mark A Clements
Journal:  J Diabetes Sci Technol       Date:  2013-09-01

Review 3.  Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters.

Authors:  Lorena Alarcon-Casas Wright; Irl B Hirsch
Journal:  Diabetes Technol Ther       Date:  2017-05       Impact factor: 6.118

Review 4.  Utility of different glycemic control metrics for optimizing management of diabetes.

Authors:  Klaus-Dieter Kohnert; Peter Heinke; Lutz Vogt; Eckhard Salzsieder
Journal:  World J Diabetes       Date:  2015-02-15

5.  The impact of basal insulin analogues on glucose variability in patients with type 2 diabetes undergoing renal replacement therapy for end-stage renal disease.

Authors:  Octavian Savu; Viviana Elian; Oana Steriade; Ileana Teodoru; Stela Mihut; Catalin Tacu; Adrian Covic; Cristian Serafinceanu
Journal:  Int Urol Nephrol       Date:  2016-01-02       Impact factor: 2.370

6.  Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes.

Authors:  Boris Kovatchev; Claudio Cobelli
Journal:  Diabetes Care       Date:  2016-04       Impact factor: 19.112

7.  Is hypoglycemia fear independently associated with health-related quality of life?

Authors:  Lizheng Shi; Hui Shao; Yingnan Zhao; Nina A Thomas
Journal:  Health Qual Life Outcomes       Date:  2014-11-30       Impact factor: 3.186

8.  Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.

Authors:  Andrea Tura; Johan Farngren; Anja Schweizer; James E Foley; Giovanni Pacini; Bo Ahrén
Journal:  Int J Endocrinol       Date:  2015-10-26       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.